Stada Arzneimittel (SAZ) Receives €73.49 Consensus Target Price from Analysts

Shares of Stada Arzneimittel (ETR:SAZ) have received a consensus recommendation of “Sell” from the seven research firms that are currently covering the company, MarketBeat.com reports. Five research analysts have rated the stock with a sell rating and two have assigned a hold rating to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is €73.49 ($85.46).

A number of brokerages recently weighed in on SAZ. Independent Research set a €89.00 ($103.49) price target on shares of Stada Arzneimittel and gave the stock a “neutral” rating in a research report on Wednesday, May 9th. Nord/LB set a €74.40 ($86.51) price target on shares of Stada Arzneimittel and gave the stock a “sell” rating in a research report on Friday, March 23rd. Warburg Research set a €74.40 ($86.51) price target on shares of Stada Arzneimittel and gave the stock a “sell” rating in a research report on Wednesday, April 4th. Finally, Cfra set a €70.00 ($81.40) price target on shares of Stada Arzneimittel and gave the stock a “sell” rating in a research report on Tuesday, May 8th.

Shares of SAZ stock traded up €0.08 ($0.09) on Friday, reaching €81.52 ($94.79). 12,939 shares of the stock were exchanged, compared to its average volume of 51,761. Stada Arzneimittel has a 1-year low of €53.41 ($62.10) and a 1-year high of €90.24 ($104.93).

About Stada Arzneimittel

STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of pharmaceutical products for the health care and pharmaceutical markets worldwide. It operates through two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidin Naloxone for pain; Atorvastatin for elevated cholesterol levels; Epoetin zeta for anemia; Diclofenac for pain/inflammation; and Pantoprazole for gastric ulcer/reflux.

Analyst Recommendations for Stada Arzneimittel (ETR:SAZ)

Receive News & Ratings for Stada Arzneimittel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stada Arzneimittel and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply